Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization

BACKGROUND: The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID‐19 may derive from neutralizing antibodies (nAbs) to SARS‐CoV‐2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging st...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvala, Heli, Nguyen, Dung, Simmonds, Peter, Lamikanra, Abigail A., Tsang, Hoi Pat, Otter, Ashley, Maes, Piet, Webster, Mhairi, Clarkson, Adam, Kaloyirou, Fotini, Hopkins, Valerie, Laidlaw, Stephen M., Carroll, Miles, Mora, Ana, Griffiths, Alexandra, MacLennan, Sheila, Estcourt, Lise, Roberts, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348319/
https://www.ncbi.nlm.nih.gov/pubmed/35588314
http://dx.doi.org/10.1111/trf.16934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348319/
https://www.ncbi.nlm.nih.gov/pubmed/35588314
http://dx.doi.org/10.1111/trf.16934

Ejemplares similares